NASDAQ:ALXO ALX Oncology Q2 2026 Earnings Results & Report $1.25 +0.07 (+5.93%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.20 -0.05 (-4.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ALX Oncology beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.13 versus the -$0.1429 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call8:00 AM ET ALX Oncology EPS ResultsActual EPS-$0.13Consensus EPS -$0.1429Beat/MissBeat by +$0.0129One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersALX Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsALX Oncology's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ALX Oncology Q2 2026 Earnings FAQ Did ALX Oncology beat earnings estimates for Q2 2026? ALX Oncology (NASDAQ:ALXO) reported earnings of -$0.13 per share for Q2 2026, beating the consensus estimate of -$0.1429. The report was announced on Thursday, August 6, 2026. When is ALX Oncology's next earnings date? ALX Oncology's next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for ALX Oncology on the company's earnings history page. ALX Oncology Earnings HeadlinesALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Rated "Moderate Buy" by Sell-Side BrokeragesOctober 4, 2026 | americanbankingnews.comAlx Oncology Holdings (ALXO)September 30, 2026 | in.investing.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2 ...September 28, 2026 | finance.yahoo.comAlx Oncology Holdings Inc. Announces Nature Medicine Publication of Aspen-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept ...September 28, 2026 | marketscreener.comMALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerSeptember 28, 2026 | globenewswire.comSee More ALX Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALX Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALX Oncology and other key companies, straight to your email. Email Address About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biopharmaceutical company focused on developing therapies that activate the immune system to fight cancer. The company’s research is centered on the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid detection and destruction by immune cells. Its lead investigational product is evorpacept, also known as ALX148, a protein therapeutic designed to block CD47 while limiting binding to red blood cells. Evorpacept is being evaluated in combination with other cancer treatments across several potential indications, including hematologic malignancies and solid tumors. The company’s programs remain investigational and are subject to clinical and regulatory outcomes. ALX Oncology was founded in 2015 and is headquartered in the San Francisco Bay Area of California. The company’s development activities are primarily focused on oncology research and clinical trials conducted with medical and research partners in the United States and internationally. Jaideep Dudell has served as the company’s president and chief executive officer.View ALX Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
